Claims for Patent: 10,123,996

Summary for Patent: 10,123,996

Title:	Macrocyclic lactone compounds and methods for their use
Abstract:	A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.5, R.sup.6, R.sup.8, M.sup.1, M.sup.2, M.sup.3, M.sup.4, M.sup.5, M.sup.6 and M.sup.7 are each independently a member selected from the group consisting of H, C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; R.sup.4, R.sup.7 and R.sup.9 are each independently selected from the group consisting of C.sub.1-6 alkoxy and OH; R.sup.10 is a member selected from the group consisting of H, --OH, --OP(O)Me.sub.2, ##STR00002## --O--(CH.sub.2).sub.n--OH and --O--(CH.sub.2).sub.m--O--(CH.sub.2).sub.o--CH.sub.3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L.sup.1 and L.sup.4 are independently selected from the group consisting of: ##STR00003## wherein each M.sup.8 is independently a member selected from the group consisting of C.sub.1-6 alkyl, OH and C.sub.1-6 hydroxyalkyl; each of L.sup.2 and L.sup.3 are independently selected from the group consisting of: ##STR00004## and salts, isomers, or N-oxides thereof.
Inventor(s):	Yan; John (Los Gatos, CA), Zheng; Xiaoxia (Mountain View, CA), Bhat; Vinayak D. (Cupertino, CA)
Assignee:	Elixir Medical Corporation (Milpitas, CA)
Application Number:	15/181,284
Patent Claims:	1. A method for the treatment or prevention of acute or chronic transplant rejection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: ##STR00327## or a salt, isomer, or N-oxide thereof, thereby treating or preventing the transplant rejection. 2. The method of claim 1, wherein the compound is used to treat or prevent acute or chronic organ or tissue transplant rejection in patients having undergone heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants. 3. The method of claim 1, wherein the compound is administered systemically, locally, or a combination thereof. 4. The method of claim 3, wherein administration is via an implant. 5. The method of claim 4, wherein the compound is released from the implant via osmotic pressure or diffusion. 6. The method of claim 4, wherein the implant is a biodegradable implant. 7. The method of claim 1 wherein the compound is administered in combination with at least one additional therapeutic agent. 8. The method of claim 7, wherein the additional therapeutic agent is a member selected from the group consisting of heparin, clopidogrel, coumadin, aspirin, ticlid, diclofenac, indomethacin, sulindac, ketoprofen, flurbiprofen, ibuprofen, naproxen, piroxicam, tenoxicam, tolmetin, ketorolac, oxaprosin, mefenamic acid, fenoprofen, nabumetone, acetaminophen, nimesulide, NS-398, flosulid, L-745337, celecoxib, rofecoxib, SC-57666, DuP-697, parecoxib sodium, JTE-522, valdecoxib, SC-58125, etoricoxib, RS-57067, L-748780, L-761066, o-(acetoxyphenyl)hept-2-ynyl sulfide (APHS), etodolac, meloxicam, S-2474, tacrolimus, hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, meprednisone, triamcinolone, paramethasone, fluprednisolone, betamethasone, dexamethasone, fludrocortisone, desoxycorticosterone, rapamycin, and cyclosporine. 9. The method of claim 7, wherein the additional therapeutic agent is a member selected from the group consisting of ranibizumab, bevacizumab, pegaptanib, volociximab, olopatadine, mydriatcs, dexamethasone, pilocarpine, tropicamide, quinolone, galentamine, fluocinolone acetonide, triamcinolone acetonide, atropine, atropine sulfate, atropine hydrochloride, atropine methylbromide, atropine methyl nitrate, atropine hyperduric, atropine N-oxide, phenylephrine, phenylephrine hydrochloride, hydroxyamphetamine, hydroxyamphetamine hydrobromide, hydroxyamphetamine hydrochloride, hydroxyamphetamine iodide, cyclopentolate, cyclopentolate hydrochloride, homatropine, homatropine hydrobromide, homatropine hydrochloride, homatropine methylbromide, scopolamine, scopolamine hydrobromide, scopolamine hydrochloride, scopolamine methylbromide, scopolamine methylnitrate, scopolamine N-oxide, tropicamide, tropicamide hydrobromide, tropicamide hydrochloride, pilocarpine, isopilocarpine, physostigmine, stearyl ammonium chloride and benzyl ammonium chloride. 10. The method of claim 1, wherein the compound is administered with a pharmaceutically acceptable excipient. 11. The method of claim 10 wherein the pharmaceutically acceptable excipient is selected from the group consisting of polymers, solvents, antioxidants, binders, fillers, disintegrants, lubricants, coatings, sweetening agents, flavoring agents, perfuming agents, stabilizers, colorants, metals, ceramics, semi-metals, preserving agents, glidants, wetting agents, emulsifying agents, suspending agents, dispensing agents, and acidifying agents. 12. The method of claim 11, wherein the compound is administered systemically or locally, or a combination thereof. 13. The method of claim 12, wherein administration of the compound is via delivery from a temporary device or an implant. 14. The method of claim 13, wherein the temporary device or implant is configured to release the compound to a body lumen or organ within an intracorporeal body. 15. The method of claim 1, wherein the effective dose of the compound is from about 0.1 mg to about 20 mg. 16. The method of claim 1, wherein the effective dose of the compound is from about 0.5 mg to about 10 mg. 17. The method of claim 1, wherein the effective dose of the compound is from about 1 mg to about 5 mg. 18. The method of claim 1, wherein the compound is racemic at the C-16 position. 19. The method of claim 1, wherein the compound has an (R)-stereochemistry at the C-16 position. 20. The method of claim 1, wherein the compound has an (S)-stereochemistry at the C-16 position. 21. The method of claim 10, wherein the pharmaceutically acceptable excipient is a polymer. 22. The method of claim 21, wherein the polymer is selected from the group consisting of polyurethane, polyethylene imine, ethylene vinyl alcohol copolymer, silicone, C-flex, nylons, polyamide, polyimide, polytetrafluoroethylene (PTFE), parylene, parylast, poly(methacrylate), poly(vinyl chloride), poly(dimethyl siloxane), poly(ethylene vinyl acetate), polycarbonate, polyacrylamide gels, poly(methyl methacrylate), poly(n-butyl methacrylate), poly(methyl methacrylate), poly(2-hydroxy ethyl methacrylate) poly(ethylene glycol methacrylates), poly(ethylene carbonate), Poly L lactide-glycolide-copolymer, poly L lactide-trimethylene carbonate copolymer and Poly L-lactide. 23. The method of claim 21, wherein the polymer is selected from the group consisting of poly (ethylene carbonate), Poly L lactide-glycolide copolymer, and poly(n-butyl methacrylate). 24. The method of claim 21, wherein the compound is present in an amount of at least 25% (w/w) in a mixture of the compound and the polymer. 25. The method of claim 24, wherein the compound is present in an amount of at least 50% (w/w). 26. The method of claim 4, wherein the amount of the compound associated with the temporary device or implant is from about 1 nanogram/cm.sup.2 to about 1000 microgram/cm.sup.2. 27. The method of claim 26, wherein the amount of the compound associated with the temporary device or implant is from about 1 microgram/cm.sup.2 to about 400 microgram/cm.sup.2. 28. The method of claim 26, wherein the amount of the compound associated with the temporary device or implant is from about 10 microgram/cm.sup.2 to about 400 microgram/cm.sup.2. 29. The method of claim 26, wherein the concentration of the compound in tissue adjacent to the implant is from about 0.001 .mu.g/gm tissue to about 1000 .mu.g/gm tissue. 30. The method of claim 1, wherein the compound is administered via an implant and; the pharmaceutically acceptable excipient comprises a polymer selected from the group consisting of poly(ethylene carbonate), Poly L lactide-glycolide copolymer, and poly(n-butylmethacrylate). 31. The method of claim 30, wherein the implant comprises an expandable structure. 32. The method of claim 30, wherein the implant comprises a scaffold formed at least in part from an open lattice. 33. The method of claim 30, wherein the implant comprises a stent. 34. The method of claim 30, wherein the implant comprises a graft.

Details for Patent 10,123,996

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2026-09-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2026-09-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2026-09-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2026-09-13
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2026-09-13